pharmacie et médicaments – Anticorps monoclonaux érénumab

This written question concerns the use of erenumab monoclonal antibodies within the French pharmaceutical system. It seeks clarification on regulatory and accessibility aspects related to this specific medical treatment. The question is posed to the French government, likely impacting patients, healthcare providers, and pharmaceutical companies involved with erenumab.